Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for effective delivery of gene therapies. We are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach.
Find locations served, office locations
- Business Type:
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation
What We’re Building
Gene vectors are the key for enabling gene therapies to reach a wider range of diseases and patients. Success in gene therapy relies on the vector’s ability to safely and precisely deliver a gene payload to the intended target cells and tissues. The efficacy of gene therapies, however, is currently limited by the roster of naturally occurring vectors, which are not optimized for disease treatment. To solve this problem and realize the full potential of gene therapy, Dyno is building multi-functional, disease-specific gene therapy vectors – enabling treatments that have never been possible before.